Anti-PD-1 therapies—a new first-line option in advanced melanoma

被引：0
|
作者：
Ryan J. Sullivan
Keith T. Flaherty
机构：
[1] Massachusetts General Hospital Cancer Center,Department of Medicine
来源：
Nature Reviews Clinical Oncology | 2015年 / 12卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Treatment with pembrolizumab, an anti-PD-1 antibody, improved progression-free survival compared with investigator-choice chemotherapy in a phase II trial in patients with advanced-stage melanoma previously treated with ipilimumab. Two subsequent independent trials have confirmed that anti-PD-1 therapy is a better option than either chemotherapy or ipilimumab in the frontline setting.
引用
收藏
页码：625 / 626
页数：1
相关论文
共 50 条
  • [1] Anti-PD-1 therapies- a new first-line option in advanced melanoma
    Sullivan, Ryan J.
    Flaherty, Keith T.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (11) : 625 - 626
  • [2] First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland
    Cybulska-Stopa, Bozena
    Pacholczak-Madej, Renata
    Kaminska-Winciorek, Grazyna
    Zietek, Marcin
    Czarnecka, Anna M.
    Piejko, Karolina
    Galus, Lukasz
    Ziolkowska, Barbara
    Kieszko, Stanislaw
    Kempa-Kaminska, Natasza
    Calik, Jacek
    Rolski, Janusz
    Salek-Zan, Agata
    Gajewska-Wicher, Katarzyna
    Drosik-Kwasniewska, Anna
    Rogala, Pawel
    Kubiatowski, Tomasz
    Suwinski, Rafal
    Mackiewicz, Jacek
    Rutkowski, Piotr
    IMMUNOTHERAPY, 2021, 13 (04) : 297 - U32
  • [3] MicroRNAs that predict the effectiveness of anti-PD-1 therapies in patients with advanced melanoma
    Nakahara, Satoshi
    Fukushima, Satoshi
    Okada, Etsuko
    Morinaga, Jun
    Kubo, Yosuke
    Tokuzumi, Aki
    Matsumoto, Sayaka
    Tsuruta-Kadohisa, Mina
    Kimura, Toshihiro
    Kuriyama, Haruka
    Miyashita, Azusa
    Kajihara, Ikko
    Jinnin, Masatoshi
    Ihn, Hironobu
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2020, 97 (01) : 77 - 79
  • [4] Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study
    van Zeijl, Michiel C. T.
    Haanen, John B. A. G.
    Wouters, Michel W. J. M.
    de Wreede, Liesbeth C.
    Jochems, Anouk
    Aarts, Maureen J. B.
    van den Berkmortel, Franchette W. P. J.
    de Groot, Jan Willem B.
    Hospers, Geke A. P.
    Kapiteijn, Ellen W.
    Piersma, Djura
    van Rijn, Rozemarijn S.
    Suijkerbuijk, Karijn P. M.
    ten Tije, Albert J.
    van der Veldt, Astrid A. M.
    Vreugdenhil, Gerard
    van der Hoeven, Koos J. M.
    van den Eertwegh, Alfons J. M.
    JOURNAL OF IMMUNOTHERAPY, 2020, 43 (08) : 256 - 264
  • [5] The efficacy and safety of chemotherapy with or without anti-PD-1 for the first-line treatment of advanced urothelial carcinoma
    Han, Fuxin
    Wu, Zhaozhen
    Chen, Jiaxin
    Liu, Meicen
    Hu, Yi
    CANCER MEDICINE, 2023, 12 (23): : 21129 - 21137
  • [6] Ipilimumab with anti PD-1 (nivovlumab or pembrolizumab) after progression on first line anti-PD-1 therapy for advanced melanoma.
    Mehmi, Inderjit
    Hill, Jordan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients
    Rauwerdink, Daan Jan Willem
    van Not, Olivier
    de Meza, Melissa
    van Doorn, Remco
    van der Hage, Jos
    van den Eertwegh, A. J. M.
    Haanen, John B.
    Aarts, Maureen J. B.
    van den Berkmortel, Franchette W. P. J.
    Blank, Christiaan U.
    Boers-Sonderen, Marye J.
    de Groot, Jan Willem B.
    Hospers, Geke A. P.
    Piersma, Djura
    van Rijn, Rozemarijn S.
    Boer, A. M. Stevense-den
    van der Veldt, Astrid A. M.
    Vreugdenhil, Gerard
    Wouters, Michel W. J. M.
    Suijkerbuijk, Karijn P. M.
    Kapiteijn, Ellen
    CANCERS, 2024, 16 (15)
  • [8] Treatment patterns and outcomes following disease progression on anti-PD-1 therapies for advanced melanoma
    Nordstrom, Beth L.
    Hamilton, Melissa
    Collins, Jenna M.
    Earle, Dennis
    Zhang, Ying
    Srivastava, Shivani
    Hernandez-Aya, Leonel
    FUTURE ONCOLOGY, 2022, 18 (11) : 1343 - 1355
  • [9] Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan
    Harada, Kentaro
    Yamamoto, Shun
    Kato, Ken
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (11) : 1333 - 1338
  • [10] Anti-PD-1 antibodies in metastatic uveal melanoma: a treatment option?
    Bender, Carolin
    Enk, Alexander
    Gutzmer, Ralf
    Hassel, Jessica C.
    CANCER MEDICINE, 2017, 6 (07): : 1581 - 1586
12345